

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster

Favresse, Julien; Gillot, Constant; Cabo, Julien; David, Clara; Dogné, Jean-Michel; Douxfils, Jonathan

Published in: International journal of infectious diseases

DOI: 10.1016/j.ijid.2024.107028

Publication date: 2024

Document Version Version created as part of publication process; publisher's layout; not normally made publicly available

Link to publication

Citation for pulished version (HARVARD): Favresse, J, Gillot, C, Cabo, J, David, C, Dogné, J-M & Douxfils, J 2024, 'Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster', *International journal of* infectious diseases, vol. 143, 107028, pp. 107028. https://doi.org/10.1016/i.ijid.2024.107028

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
 You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1 and JN.1 six months after the BNT162b2 bivalent booster

Julien Favresse, Constant Gillot, Julien Cabo, Clara David, Jean-Michel Dogné, Jonathan Douxfils

 PII:
 S1201-9712(24)00099-7

 DOI:
 https://doi.org/10.1016/j.ijid.2024.107028

 Reference:
 IJID 107028

To appear in: International Journal of Infectious Diseases

Received date:	16 January 2024
Revised date:	14 March 2024
Accepted date:	26 March 2024

Please cite this article as: Julien Favresse, Constant Gillot, Julien Cabo, Clara David, Jean-Michel Dogné, Jonathan Douxfils, Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1 and JN.1 six months after the BNT162b2 bivalent booster, *International Journal of Infectious Diseases* (2024), doi: https://doi.org/10.1016/j.ijid.2024.107028

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Highlights :

- Omicron (sub)variant neutralizing capacity was reduced compared to WT and Delta.
- Lowest neutralizing response was observed with the FL.1.5.1.
- Results support the need to use vaccine antigens that target circulating variants.

Junalpropho

Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1 and JN.1 six months after the BNT162b2 bivalent booster

Julien Favresse^{1,2*}, Constant Gillot^{1*,†}, Julien Cabo², Clara David³, Jean-Michel Dogné¹, Jonathan Douxfils^{1,3,4}.

¹Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.

²Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.

³Qualiblood s.a., Research and Development Department, Namur, Belgium.

⁴Department of Biological Hematology, Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France

*contributed equally

[†]Correspondence:

Constant Gillot

Clinical Pharmacology and Toxicology Research

Unit,

University of Namur

B-5000 Namur, Belgium

Phone +32 81 72 42 92

Email: constant.gillot@unamur.be

Running title: Humoral and cellular response 6 months after the bivalent booster.

Keywords: XBB.1.5, BA.2.86, FL.1.5.1, JN.1, SARS-CoV-2, bivalent booster, humoral response, Omicron.

Words (manuscript): 1,221.

Words (manuscript): 194.

Number authors: 6.

Number of references (main text): 9.

Number of tables: 0.

Number of figures: 2.

Supplemental tables: 1.

Competing Interests: The authors declare that there are no competing interests.

Author contribution: Conceptualization: JF and JD; methodology: JF, CG, JC, CD and JD; software: JF, CG and JD; validation: JF and JD; formal analysis: JF, CG and JD; investigation: JF, CG, JC, and JD; resources: JMD, and JD; data curation: JF, CG, and JC; writing–original draft preparation, JF; writing–review and editing, JF, CG, JC, CD, JMD, and JD; supervision: JD; project administration: JF and JD; funding acquisition: JF, JMD and JD. All authors have read and agreed to the published version of the manuscript.

Abstract

Introduction: An increase evasion of the SARS-CoV-2 virus towards vaccination strategies and natural immunity has been rapidly described notably due to mutations in the spike receptor binding domain and the N-terminal domain.

Material and methods: Participants of the CRO-VAX HCP study who received the bivalent booster were followed at 6 months. A pseudovirus-neutralization test was used to assess the neutralization potency of antibodies against D614G, Delta, BA.1, BA.5, XBB.1.5, BA.2.86, FL.1.5.1, and JN-1.

Results: The neutralizing capacity of antibodies against Omicron variant or subvariants was significantly reduced compared to D614G and Delta (p<0.0001). The lowest neutralizing response that was observed with JN-1 (GMT=22.1) was also significantly lower compared to XBB.1.5 (GMT=29.5, p<0.0001), BA.2.86

(GMT=29.6, p<0.0001), and FL.1.5.1 (GMT=25.2, p<0.0001). Participants that contracted a breakthrough infection due to XBB.1.5 had significantly higher neutralizing antibodies against all variants compared to uninfected participants, especially against Omicron variant and subvariants.

Conclusion:

Our results confirm that JN.1 is one of the most immune evading variants to date and that the BA.2.86 subvariant did not show an increased immunity escape compared to XBB.1.5. The stronger response in BKI with Omicron variant and subvariants supports the need to use vaccine antigens that target circulating variants.

Introduction

An increase evasion of the SARS-CoV-2 virus towards vaccination strategies and natural immunity has been rapidly described notably due to mutations in the spike receptor binding domain (RBD) and the N-terminal domain (NTD)C.

At the end of January 2020, the D614G mutation emerged in UK and rapidly became dominant in the world. In late 2020, the Delta variant was identified, bearing 9 mutations in spike[1] followed in November 2021 by the Omicron variant that presented 32 spike mutations compared to the D614G strain[2]. More recently (August 2023), the BA.2.86 subvariant was identified and characterized by 60 amino acid changes, predominantly in RBD and NTD, compared to the wild-type (WT) strain[3, 4]. The BA.2.86 subvariant has over 30 mutations in spike in comparison with BA.2 and XBB.1.5[5]. The FL.1.5.1, also known as XBB.1.9.1.1.5.1, presents 3 additional mutations in spike compared to XBB.1.5 (i.e., F456L, T478R, and A701V)[5]. In late 2023, the BA.2.86 has evolved in JN.1 and rapidly became

dominant. It is characterized with one additional RBD mutation (L455S) and 3 other non-spike mutations[6, 7].

The presence of these mutations raised the possibility of an increase in neutralizing antibody evasion[5].

The aim of the study was to evaluate the impact of recent circulating SARS-CoV-2 subvariants on the neutralizing antibody response of individuals who had been followed for 6 months after having received the bivalent booster.

Material and methods

Study design

The CRO-VAX-HCP study is a Belgian multicenter, perspective, and interventional study that was designed to assess the humoral response in a population of healthcare workers (HCW) from 18 to 65 years having received two doses of the BNT162b2 mRNA COVID-19 vaccine followed by a homologous booster (third dose) and after by a bivalent booster (BA.1 or BA.4/5; fourth dose) (ethical approval number: 2020-006149-21) (**Supplemental Table 1**). In the present study, we compared the neutralizing antibody response against D614G, Delta, BA.1, BA.5, XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 6 months after the bivalent booster administration in a population of 30 participants.

- Seroneutralization

A pseudovirus-neutralization test was used to assess the neutralization potency of antibodies against 8 variants (D614G, Delta, BA.1, BA.5, XBB.1.5, BA.2.86, FL.1.5.1, and JN.1). The antibody titer is determined as the dilution of serum at which 50% of the infectivity is inhibited (IC_{50}) as determined by a nonlinear sigmoid regression model. Method details have been described elsewhere[8].

5

- Statistical analysis

The normality of distribution was assessed by the Anderson-Darling's test following log-transformation. Median and interquartile range (IQR) were used to present demographic data and geometric mean titers (GMT) and 95% confidence intervals (95%Cls) to present the results of the humoral response. A multiple comparison test (two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli) was used to assess the potential difference between the type of variants. A Mann-Withney test was used to compare age between genders and to compare neutralizing antibody titers between participants that developed a breakthrough infection (BKI) or not. Statistical analyses were performed using GraphPad Prism 10.2.0 (GraphPad Software, Massachusetts, USA). p<0.05 was considered significant.

Results

- Demographics

Twenty-one were females (median age=55 years; IQR=44–59) and 9 were males (median age =54years; IQR=41–60). Ages were non-significantly different between females and males (p=0.90). Most of the participants (25/30; 83%) had a history of SARS-CoV-2 infection (BA.1) before the administration of the bivalent booster. Twenty-six participants received the BA.1 adapted booster while 4 received the BA.4/5 adapted booster. Six participants development a BKI due to XBB.1.5, 3–6 months after the bivalent booster administration (**Supplemental Table 1**).

- Neutralizing capacity

Bivalent-booster sera obtained at 6 months neutralized D614G, Delta, BA.1, BA.5, XBB.1.5, BA.86, FL.1.5.1, and JN.1 with GMT of 319, 162, 71.6, 61.4, 29.5, 29.6, 25.2, and 22.1, respectively (**Figure 1**). The neutralizing capacity of antibodies

against Omicron variant or subvariants was significantly reduced compared to D614G and Delta variants (p<0.0001). The lowest neutralizing response that was observed with JN.1 (GMT=22.1, 95%CI: 16.2–30.2) was also significantly lower compared to XBB.1.5 (GMT=29.5, 95%CI: 21.4–40.6; p=0.0002), BA.2.86 (GMT=29.6, 95%CI: 21.4–41.0; p=0.0003), and FL.1.5.1 (GMT=25.2, 95%CI: 18.1-34.9; p=0.0094) (Figure 1).

The level of neutralizing antibodies against Delta, BA.1, BA.5, XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 were 1.97, 4.46, 5.20, 10.81, 10.77, 12.67, and 14.43 lower compared to D614G. Compared to XBB.1.5, BA.2.86, and FL.1.5.1, the neutralizing capacity of antibodies against JN.1 was 1.33, 1.34, and 1.14-fold-decrease, respectively (**Figure 1**).

Participants that contracted a BKI had significantly higher neutralizing antibodies against all variants (i.e., cross-reactivity) compared to uninfected participants. The fold change was more pronounced with BA.1, BA.5, XBB.1.5., BA.2.86, FL.1.5.1, and JN.1 (fold change ranging 4.5–5.0) compared to D614G (fold change=2.5) and Delta (fold change=3.0) (**Figure 2**).

Discussion

The administration of COVID-19 vaccines allowed the reduction of SARS-CoV-2 infections, complications and death. A gradual decline in vaccine efficacy (VE) against infection was however rapidly observed. This waned efficacy was consistent with the decrease of neutralizing antibodies, supporting their role as a strong correlation of COVID-19 protection from infection. The decrease in VE was further heightened by the emergence of variants, especially the Omicron variant and its

subvariants[2, 5, 8, 9]. For instance, a 23.1-fold decrease of NAbs against BA.5 was observed between one and 6 months after the bilvant booster ($T_{1/2}$ =16.1 days)[10]. Recently, some concerns were formulated following the identification of the BA.2.86 subvariant that could more easily escape immunity because of its high number of additional mutations compared to XBB.1.5.[3, 5]. This has not happened[11] and was confirmed in our study and by others by the identification of similar neutralizing antibody titers between BA.2.86 and XBB.1.5[5, 9]. In accordance with our evaluation, Hu *et al.* identified that neutralizing antibody response of FL.1.5.1 was also lower compared to BA.2.86 and XBB.1.5. in a population of 48 individuals 14–32 days after the bivalent booster [12].

Compared to BA.2.86, the JN.1 has become the predominant subvariant[6, 13]. Yang *et al.* found an enhance immune escape of JN.1 compared to BA.2.86 (1.1 to 2.1-fold decrease in the 50% neutralization titer (NT₅₀) (n=54)[7]. Kaku *et al.* pointed a 4.5-fold decrease in NT₅₀ of JN.1 compared to BA.2.86 3-4 weeks after XBB.1.5 vaccination (n=19)[6]. Planas *et al.* confirmed a 2.0-fold neutralization decreased between BA.2.86 and JN.1 after 3 doses of BNTA62b2 (n=13) and 6 months after the BA.5 bivalent booster (n=8)[14]. A less pronounced decreased of 1.15-fold was also observed by Jeworowski *et al.* compared to BA.2.86[13] and is in line with the present study.

Interestingly, individuals who developed a XBB.1.5 BKI in our study presented a boost in neutralizing antibodies against all variants and subvariants compared to uninfected individuals, but mostly on Omicron variants and subvariants, supporting the need to consider the use of vaccines that are adapted to circulating variants, as recommended by the WHO and the FDA[9, 12]. Similar results have been found in

8

two studies in individuals who developed an XBB.1.5 BKI or who received the XBB .1.5 monovalent vaccine[11, 14].

The sample size of our study was low, especially considering the subcohort of participants that developed a BKI. This represents a limitation.

Conclusion

Our results confirm that JN.1 is one of the most immune evading variants to date and that the BA.2.86 subvariant did not show an increased immunity escape compared to XBB.1.5. The fact that only the reduced neutralizing capacity might be the only mechanism that could explain why JN.1 rapidly became predominant need further evaluations. The boost in neutralizing antibody titers observed in subjects who developed a BKI after the administration of the bivalent booster was mostly superior considering Omicron variants and subvariant. This supports the need to use vaccine antigens that target circulating variants.

Conflict of interest: The authors declare no conflict of interest.

Funding source: The authors declare no funding.

Ethical statement: The study was in accordance with the declaration of Helsinki (ethical approval number: 2020-006149-21).

References

- D. Tian, Y. Sun, J. Zhou, and Q. Ye, "The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape," *Front Immunol*, vol. 12, p. 751778, 2021, doi: 10.3389/fimmu.2021.751778.
- [2] D. Planas *et al.*, "Considerable escape of SARS-CoV-2 Omicron to antibody neutralization," *Nature*, vol. 602, no. 7898, pp. 671-675, Feb 2022, doi: 10.1038/s41586-021-04389-z.
- [3] A. S. Lambrou *et al.*, "Early Detection and Surveillance of the SARS-CoV-2 Variant BA.2.86 - Worldwide, July-October 2023," *MMWR Morb Mortal Wkly Rep*, vol. 72, no. 43, pp. 1162-1167, Oct 27 2023, doi: 10.15585/mmwr.mm7243a2.
- [4] R. Lassauniere *et al.*, "Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1," *Lancet Infect Dis*, vol. 23, no. 12, pp. e509-e510, Dec 2023, doi: 10.1016/S1473-3099(23)00682-5.
- [5] N. Lasrado *et al.*, "Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86," *Vaccine*, vol. 41, no. 47, pp. 6904-6909, Nov 13 2023, doi: 10.1016/j.vaccine.2023.10.051.
- [6] Y. Kaku *et al.*, "Virological characteristics of the SARS-CoV-2 JN.1 variant," *Lancet Infect Dis*, vol. 24, no. 2, p. e82, Feb 2024, doi: 10.1016/S1473-3099(23)00813-7.
- S. Yang *et al.*, "Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure," *Lancet Infect Dis*, vol. 24, no. 2, pp. e70-e72, Feb 2024, doi: 10.1016/S1473-3099(23)00744-2.
- [8] J. Favresse *et al.*, "Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster," *J Med Virol*, vol. 95, no. 1, p. e28164, Jan 2023, doi: 10.1002/jmv.28164.
- [9] B. J. Willett *et al.*, "Omicron BA.2.86 cross-neutralising activity in community sera from the UK," *Lancet*, vol. 402, no. 10417, pp. 2075-2076, Dec 2 2023, doi: 10.1016/S0140-6736(23)02397-8.
- [10] J. Favresse *et al.*, "Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster," *J Med Virol*, vol. 96, no. 1, p. e29365, Jan 2024, doi: 10.1002/jmv.29365.
- [11] Q. Wang *et al.*, "XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1," *Cell Host Microbe*, Feb 10 2024, doi: 10.1016/j.chom.2024.01.014.
- [12] Y. Hu *et al.*, "Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1," *Emerg Microbes Infect*, vol. 12, no. 2, p. 2271089, Dec 2023, doi: 10.1080/22221751.2023.2271089.
- [13] L. M. Jeworowski *et al.*, "Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023," *Euro Surveill*, vol. 29, no. 2, Jan 2024, doi: 10.2807/1560-7917.ES.2024.29.2.2300740.
- [14] D. Planas *et al.*, "Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion," *bioRxiv*, Feb 9 2024, doi: 10.1101/2023.11.20.567873.

Figure 1: Comparison of the neutralizing capacity against the D614G strain (WT), the Delta, the BA.1 Omicron variant, the BA.5 Omicron variant, the XBB.1.5 Omicron subvariant, the BA.2.86 Omicron subvariant, and the FL.1.5.1 Omicron subvariant in a population of 30 healthy volunteers 6 months after having received the bivalent booster. Geometric mean titers (GMT) (\pm 95% CI) and percentage of positive samples are represented. The block dotted line represents the positivity cut-offs for neutralizing antibodies (IC₅₀ of 1:20). The grey dotted line represents the limit of detection of the assay (IC₅₀ of 10). * = significantly higher compared to all other variants (p<0.0001). ** = significantly higher compared to all other variants (p<0.0001).





Figure 2: Comparison of the neutralizing capacity against the D614G strain (WT), the Delta, the BA.1 Omicron variant, the BA.5 Omicron variant, the XBB.1.5 Omicron subvariant, the BA.2.86 Omicron subvariant, and the FL.1.5.1 Omicron subvariant in individuals who developed a breakthrough infection following administration of the bivalent booster or not. Blood was collected 6 months after having received the bivalent booster. Geometric mean titers (GMT) (\pm 95% CI) are represented as well as the fold-difference between groups. The block dotted line represents the positivity cut-offs for neutralizing antibodies (IC₅₀ of 1:20). The grey dotted line represents the limit of detection of the assay (IC₅₀ of 10).



Declaration of interests

 \boxtimes The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

□ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: